ONCOLOGY

Robotic-assisted surgery may attenuate risk in patients with CKD.

Phase 3 ARCHES trial reports 61% reduction in risk for progression or death.

Large multicenter retrospective analysis compares ENRT and SBRT.

The proposed recommendations are based on a review of existing guidance and published literature.

Concurrent radiotherapy with ADT advised for low-burden metastatic disease.

Patients with negative scans show a low risk for cancer at follow-up.

A recent study suggests the risk of meningioma remains increased at least one year after cessation of treatment.

Phase 2 study reported QoL preservation.

Uptake more rapid in younger patients, but overall use remains lower.

LRP1b mutations are a potential marker for response.

10-year follow-up data for survival, side-effects, and cost.

Findings warrant careful evaluation of risk-benefit ratio.

Randomized study reported mineralocorticoid adverse effects of 4 regimens.

Phase 3 HYPO-RT-PC trial reported similar 5-year adverse effect profile.